Effect of Water Molecules on the Activating S810L Mutation of the Mineralocorticoid Receptor

The mineralocorticoid receptor (MR) is a nuclear receptor whose endogenous ligands are mineralocorticoids, a type of steroid hormone. The activating S810L mutation is known to cause severe early-onset and pregnancy-related hypertension. Progesterone binds to the wild-type (WT) MR as a passive antagonist with fast dissociation; however, it binds to the S810L mutant as a full agonist with slow dissociation. The switch in the biological activity of progesterone is considered to be one of the causes of the disease. First, we used steered molecular dynamics simulations to analyze the dissociation process of progesterone for the WT and the S810L mutant. Progesterone in the WT dissociated from the ligand-binding pocket with a weak force in comparison with progesterone in the S810L mutant due to the large inflow of water molecules into the pocket. Therefore, we used conventional molecular dynamics simulations for the ligand-free structures of the WT and the S810L mutant to investigate the effect of the mutation on the inflow of water. In the WT, water molecules enter the ligand-binding pocket in two ways: in the vicinity of (i) Arg817 and (ii) Ser810. In contrast, few water molecules enter the pocket in the S810L mutant because of the large size and hydrophobic nature of the Leu810 side chain. Fast dissociation is a common feature among passive antagonists of MR; therefore, we inferred that the water inflow could be responsible for the dissociation kinetics of progesterone in the WT and the S810L mutant.

[1]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.

[2]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[3]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[4]  B. Rossier,et al.  Aldosterone regulation of gene transcription leading to control of ion transport. , 1992, Hypertension.

[5]  Tobias Hüfner-Wulsdorf,et al.  Role of Water Molecules in Protein-Ligand Dissociation and Selectivity Discrimination: Analysis of the Mechanisms and Kinetics of Biomolecular Solvation Using Molecular Dynamics , 2020, J. Chem. Inf. Model..

[6]  Timothy M Willson,et al.  A Ligand-mediated Hydrogen Bond Network Required for the Activation of the Mineralocorticoid Receptor*[boxs] , 2005, Journal of Biological Chemistry.

[7]  J. Fagart,et al.  Sulfhydryl groups are involved in the binding of agonists and antagonists to the human mineralocorticoid receptor , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  F. J. Luque,et al.  Shielded hydrogen bonds as structural determinants of binding kinetics: application in drug design. , 2011, Journal of the American Chemical Society.

[9]  M. Agarwal,et al.  General overview of mineralocorticoid hormone action. , 1999, Pharmacology & therapeutics.

[10]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[11]  T. Nyrönen,et al.  Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain. , 2005, Journal of medicinal chemistry.

[12]  M. Makishima,et al.  2-Methylene 19-nor-25-dehydro-1alpha-hydroxyvitamin D3 26,23-lactones: synthesis, biological activities and molecular basis of passive antagonism. , 2008, Bioorganic & medicinal chemistry.

[13]  G. Piwien-Pilipuk,et al.  Modification of an essential amino group in the mineralocorticoid receptor evidences a differential conformational change of the receptor protein upon binding of antagonists, natural agonists and the synthetic agonist 11,19-oxidoprogesterone. , 2002, Biochimica et biophysica acta.

[14]  P. Kollman,et al.  Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.

[15]  M Carlquist,et al.  Structural insights into the mode of action of a pure antiestrogen. , 2001, Structure.

[16]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[17]  André Fischer,et al.  Ligand Pathways in Nuclear Receptors , 2019, J. Chem. Inf. Model..

[18]  J. Edwards,et al.  5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators. , 2003, Journal of medicinal chemistry.

[19]  David A. Agard,et al.  Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism , 2002, Nature Structural Biology.

[20]  Hideki Matsui,et al.  Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists. , 2011, Journal of medicinal chemistry.

[21]  P. Sigler,et al.  Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. , 2000, Science.

[22]  V. Lin,et al.  Exploring Flexibility of Progesterone Receptor Ligand Binding Domain Using Molecular Dynamics , 2016, PloS one.

[23]  J D Baxter,et al.  The nuclear hormone receptor gene superfamily. , 1995, Annual review of medicine.

[24]  C. Hellal-Levy,et al.  Mechanistic aspects of mineralocorticoid receptor activation. , 2000, Kidney international.

[25]  E. Baulieu,et al.  Differential intracellular localization of human mineralocorticosteroid receptor on binding of agonists and antagonists. , 1994, The Biochemical journal.

[26]  Vincent Le Guilloux,et al.  Fpocket: An open source platform for ligand pocket detection , 2009, BMC Bioinformatics.

[27]  M. Kawata,et al.  Dynamic changes in subcellular localization of mineralocorticoid receptor in living cells: in comparison with glucocorticoid receptor using dual-color labeling with green fluorescent protein spectral variants. , 2001, Molecular endocrinology.

[28]  A. Vandewalle,et al.  Identification of steroid ligands able to inactivate the mineralocorticoid receptor harboring the S810L mutation responsible for a severe form of hypertension , 2004, Molecular and Cellular Endocrinology.

[29]  M. Lombès,et al.  Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure. , 1996, The Biochemical journal.

[30]  J. Fagart,et al.  Structural determinants of ligand binding to the mineralocorticoid receptor , 2012, Molecular and Cellular Endocrinology.

[31]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[32]  J. Fagart,et al.  The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. , 1995, Endocrinology.

[33]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[34]  C. Gomez-Sanchez,et al.  Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors , 1999, FEBS letters.

[35]  Dan Li,et al.  Structural Diversity of Ligand-Binding Androgen Receptors Revealed by Microsecond Long Molecular Dynamics Simulations and Enhanced Sampling. , 2016, Journal of chemical theory and computation.

[36]  M. Lambert,et al.  Activation of nuclear receptors: a perspective from structural genomics. , 2003, Structure.

[37]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[38]  J. Gustafsson,et al.  Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation. , 2003, Molecular endocrinology.

[39]  M. Lombès,et al.  Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1* , 2015, The Journal of Biological Chemistry.

[40]  H. Gronemeyer,et al.  Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. , 2000, Trends in pharmacological sciences.

[41]  P. Fuller,et al.  Mineralocorticoid action , 2000, Steroids.

[42]  Victor Guallar,et al.  Ligand Binding Mechanism in Steroid Receptors: From Conserved Plasticity to Differential Evolutionary Constraints. , 2015, Structure.

[43]  Ly Le,et al.  Steered Molecular Dynamics Simulation in Rational Drug Design , 2018, J. Chem. Inf. Model..

[44]  M. Lombès,et al.  A new strategy for selective targeting of progesterone receptor with passive antagonists. , 2013, Molecular endocrinology.

[45]  J. Gies,et al.  Drugs and their molecular targets: an updated overview , 2008, Fundamental & clinical pharmacology.

[46]  D. Moras,et al.  Antagonism in the human mineralocorticoid receptor , 1998, The EMBO journal.

[47]  Alexander Hillisch,et al.  A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule* , 2010, The Journal of Biological Chemistry.

[48]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[49]  E. Baulieu,et al.  Differences between aldosterone and its antagonists in binding kinetics and ligand-induced hsp90 release from mineralocorticosteroid receptor , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[50]  Norma Roxana Carina Alves,et al.  Structural Insights into the Ligand Binding Domain of the Glucocorticoid Receptor: A Molecular Dynamics Study , 2019, J. Chem. Inf. Model..